In estrogen receptor-positive/human epidermal growth factor
receptor 2-negative (ER+/HER2-) advanced/metastatic breast cancer
KNOWING THE ESR1 MUTATION STATUS
CAN MAKE ALL THE DIFFERENCE
Testing to know the tumor mutation status can help decide the next best treatment option
Meet Lisa, and explore her story on this website. You'll see Lisa portrayed in many ways, reflecting the diverse experiences of individuals facing advanced or metastatic breast cancer. While "Lisa" may have many faces here, her story embodies the shared journey of countless others.
Not an actual patient
Advanced/metastatic
breast cancer
Lisa is a third-grade teacher who leads
a very active life. She is also a person
living with ER+/HER2- advanced or
metastatic breast cancer.
advanced/metastatic breast cancer
Not an actual patient
ESR1 mutations in a/mBC
Like many people with the same cancer type as
Lisa, she was taking hormone therapy and a type
of treatment called a cyclin-dependent kinase 4/6 (CDK4/6) inhibitor.
After a little over a year, the disease had progressed, so the
healthcare team told Lisa it was time to try a
different treatment.
ESR1 mutations in a/mBC
Not an actual patient
When to be tested
for ESR1 mutations
Lisa learned that ESR1 mutations commonly
develop in cancer cells after treatment like hers.
So, before starting the next treatment, she asked her
oncologist about the ESR1 mutation status of her
cancer. She was tested and it was determined that
her cancer had developed an ESR1 mutation. Now
that she knows the cancer ESR1 mutation status,
she is discussing treatment options specifically for
her type of cancer with the healthcare team.
ESR1 mutation testing
Not an actual patient
ESR1 FAQs
There may be many questions
about ESR1 mutations and a/mBC.
Here are some answers.
answers to FAQs
Not an actual patient
a/mBC: advanced/metastatic breast cancer; CDK4/6: cyclin-dependent kinase 4/6; ER+: estrogen receptor-positive; ESR1: estrogen receptor 1; FAQs: frequently asked questions; HCP: healthcare professional; HER2-: human epidermal growth factor receptor 2-negative.
